Author: Yann Godfrin

📢Second DSMB review completed: Confirmation of a satisfactory safety and tolerability profile for NX210c Axoltis Pharma is pleased to announce that the Data Safety Monitoring Board (DSMB) has completed its second safety review of a cohort of the first 50 patients of the SEALS study and confirmed a good safety profile of NX210c. SEALS is a multicenter, … Continued

2 December, 2025 Axoltis Pharma, a biotech company dedicated to developing novel therapeutic solutions for neurodegenerative diseases, today announces the closing of a Series A funding round worth €18 million ($20.9M), to be disbursed in two installments. The funding, which includes new and historic investors, will enable the company to pursue the development of NX210c, its … Continued

15 November, 2024